A TP53-associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma.

ABSTRACT: The tumor-suppressor gene tumor protein p53 (TP53) is one of the most commonly mutated genes in human lung cancer, and TP53 mutations are associated with a worsened prognosis and causes resistance to cancer therapy. RNA sequencing and TP53 mutation data were downloaded to determine specific TP53-associated signature based on differentially expressed genes between patients with lung squamous cell carcinoma (LUSC) with wild type (TP53  ^WT) and mutated (TP53 ^MUT) TP53. We investigated the predictive value of this signature on the immune microenvironment, tumor mutational burden (TMB), and likelihood of response to immunotherapy and chemotherapy. In total, 1,556 differentially expressed genes were identified based on TP5

SUBMITTER: Xu F 

PROVIDER: S-EPMC7051188 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature